Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 14, 2008, Pages 6965-6975

  Penning, Thomas D ^a   Zhu, Gui Dong ^a   Gandhi, Viraj B ^a   Gong, Jianchun ^a   Thomas, Sheela ^a   Lubisch, Wilfried ^b   Grandel, Roland ^b   Wernet, Wolfgang ^b   Park, Chang H ^a   Fry, Elizabeth H ^a   Liu, Xuesong ^a   Shi, Yan ^a   Klinghofer, Vered ^a   Johnson, Eric F ^a   Donawho, Cherrie K ^a   Frost, David J ^a   Bontcheva Diaz, Velitchka ^a   Bouska, Jennifer J ^a   Olson, Amanda M ^a   Marsh, Kennan C ^a   Luo, Yan ^a   Rosenberg, Saul H ^a   Giranda, Vincent L ^a   more..

^a ABBOTT LABORATORIES   (United States)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

A 620223; Benzimidazole carboxamide; PARP inhibitor; Poly(ADP ribose)polymerase

Indexed keywords

2 (1 PROPYLPIPERIDIN 4 YL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; A 620223; ANTINEOPLASTIC AGENT; CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CELL ASSAY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; IN VIVO STUDY; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BREAST NEOPLASMS; CISPLATIN; DACARBAZINE; ENZYME INHIBITORS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; POLY(ADP-RIBOSE) POLYMERASES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE;

EID: 47549095368     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.05.044     Document Type: Article

References (24)

1. Virág L., and Szabó C. Pharmacol. Rev. 54 (2002) 375-429
2. Munoz-Gamez J.A., Martin-Oliva D., Aguilar-Quesada R., Canuelo A., Nunez M.I., Valenzuela M.T., Ruiz de Almodovar J.M., de Murcia G., and Oliver J.A. Biochem. J. 386 (2005) 119-125
3. Tentori L., and Graziani G. Pharmacol. Res. 52 (2005) 25-33
4. Shirou S., Nomura F., Tomonaga T., Sunaga M., Noda M., Ebara M., and Saisho H. Oncol. Rep. 12 (2004) 821-825
5. Griffin R.J., Curtin N.J., Newell D.R., Golding B.T., Durkacz B.W., and Calvert A.H. Biochemie 77 (1995) 408-422
6. Plummer E.R. Curr. Opin. Pharmacol. 6 (2006) 364-368
7. Horváth E.M., and Szabó C. Drug News Perspect. 20 (2007) 171-181
8. Ratnam K., and Low J.A. Clin. Cancer Res. 13 (2007) 1383-1388
9. Donawho C.K., Luo Y., Luo Y., Penning T.D., Bauch J.L., Bouska J.J., Bontcheva-Diaz V.D., Cox B.F., DeWeese T.L., Dillehay L.E., Ferguson D.C., Ghoreishi-Haack N.S., Grimm D.R., Guan R., Han E.K., Holley-Shanks R., Hristov B., Idler K.B., Jarvis K., Johnson E.F., Kleinberg L.E., Klinghofer V., Lasko L.M., Liu X., Marsh K.C., McGonigal T.P., Meulbroek J.A., Olson A.M., Palma J.P., Rodriguez L.E., Shi Y., Stavropoulos J.A., Tsurutani A.C., Zhu G.-D., Rosenberg S.H., Giranda V.L., and Frost D.J. Clin. Cancer Res. 13 (2007) 2728-2737
10. Lapidus R.G., Tentori L., Graziani G., Leonetti C., Scarsella M., Vergati M., Muzi A., and Zhang J. J. Clin. Oncol. 23 (2005) 3136
11. Calabrese C.R., Almassy R., Barton S., Batey M.A., Calvert A.H., Canan-Koch S., Durkacz B.W., Hostomsky Z., Kumpf R.A., Kyle S., Li J., Maegley K., Newell D.R., Notarianni E., Stratford I.J., Skalitsky D., Thomas H.D., Wang L.-Z., Webber S.E., Williams K.J., and Curtin N.J. J. Natl. Cancer Inst. 96 (2004) 56-67
12. Tentori L., Leonetti C., Scarsella M., d'Amati G., Vergati M., Portarena I., Xu W., Kalish V., Zupi G., Zhang J., and Graziani G. Clin. Cancer Res. 9 (2003) 5370-5379
13. Li J.-H., and Zhang J. IDrugs 4 (2001) 804-812
14. Cockcroft X., Dillon K.J., Dixon L., Drzewiecki J., Kerrigan F., Loh V.M., Martin N.M.B., Menear K.A., and Smith G.C.M. Bioorg. Med. Chem. Lett. 16 (2006) 1040-1044
15. Ferraris D., Ficco R.P., Dain D., Ginski M., Lautar S., Lee-Wisdom K., Linag S., Lin Q., Lu M.X.-C., Morgan L., Thomas B., Williams L.R., Zhang J., Zhou Y., and Kalish V.J. Bioorg. Med. Chem. 11 (2003) 3695-3707
16. Canan-Koch S.S., Thoresen L.H., Tikhe J.G., Maegley K.A., Yu X.-H., Zook S.E., Kumpf R.A., Zhang C., Boritzki T.J., Mansour R.N., Zhang K.E., Ekker A., Calabrese C.R., Curtin N.J., Kyle S., Thomas H.D., Wang L.-Z., Calvert A.H., Golding B.T., Griffin R.J., Newell D.R., Webber S.E., and Hostomsky Z. J. Med. Chem. 45 (2002) 4961-4974
17. Costatino G., Macchiarulo A., Camaioni E., and Pellicciari R. J. Med. Chem. 44 (2001) 3786-3794
18. Barkalow J.H., Breting J., Gaede B.J., Haight A.R., Henry R., Kotecki B., Mei J., Pearl K.B., Tedrow J.S., and Viswanath S.K. Org. Process Res. Dev. 11 (2007) 693-698
19. Lubisch, W.; Kock, M.; Hoeger, T.; Grandel, R.; Schult, S.; Mueller, R. Cyclo-alkyl substituted benzimidazoles and their use as PARP inhibitors. U.S. Patent 6,737,421, 2004.
20. White A.W., Curtin N.J., Eastman B.W., Golding B.T., Hostomsky Z., Kyle S., Li J., Maegley K.A., Skalitzky D.J., Webber S.E., Yu X.-H., and Griffin R.J. Bioorg. Med. Chem. Lett. 14 (2004) 2433-2437
21. Hattori K., Kido Y., Yamamoto H., Ishida J., Kamijo K., Murano K., Ohkubo M., Kinoshita T., Iwashita A., Mihara K., Yamazaki S., Matsuoka N., Teramura Y., and Miyake H. J. Med. Chem. 47 (2004) 4151-4154
22. Okamoto, Y.; Kubota, H.; Sato, I.; Hattori, K.; Kanayama, T.; Yokoyama, K.; Terai, Y.; Takeuchi, M. 2-Aminopyridine derivative. PCT Int. Appl. WO 2005100341, 2005.
23. Lubisch, W.; Kock, M.; Höger, T.; Schult, S.; Grandel, R.; Müller, R. Substituted benzimidazoles and their use as PARP inhibitors. U.S. Patent 6,448,271, 2002.
24. Ishida J., Yamamoto H., Kido Y., Kamijo K., Murano K., Miyake H., Ohkubo M., Kinoshita K., Warizaya M., Iwashita A., Mihara K., Matsuoka N., and Hattori K. Bioorg. Med. Chem. 14 (2006) 1378-1390